Haploidentical and cord blood transplantation activities in Europe, the US, and China. (A) Haplo-SCT and CBT for AML and ALL in Europe (Acute Leukemia Working Party of the EBMT). Data include non–T-cell- depleted and T-cell depleted haplo-SCT, single CTB, and double CBT in 2000-2020. (B) Haplo-SCT and CBT in Europe in adult and pediatric populations in 2000-2020. Data include haplo-SCT and CBT for various hematological malignancies (AML, ALL, MDS, MPN [myeloproliferative neoplasms], NHL) in 2020. (C) Haplo-SCT and CBT in the US (CIBMTR) in 2000-2020 for various hematological malignancies (AML, ALL, MDS/MPN, NHL, HL) and nonmalignant diseases, excluding SAA, modified from CIBMTR 2021 summary slides. Data include adults (>18 years) and children and adolescents (<18 years) and BM and PB (peripheral blood) grafts, with MAC or RIC/NMA (nonmyeloablative conditioning). (D) Haplo- SCT (HID) and CBT in China (Chinese Blood and Marrow Transplantation Registry Group) in 2008-2021. Data are for haplo-SCT and CBT in various hematological malignancies (AML, ALL, MDS, NHL) in 2021. peds, pediatric patients; SCBT; single cord blood transplantation; URD, unrelated donor transplant.